Scholar Rock Reports Q3 2026 Results Following ISEMBYLD FDA Approval
Scholar Rock (SRRK) reported its third-quarter 2026 financial results, highlighted by the recent FDA approval of ISEMBYLD on September 11, 2026. The company generated $0.6 million in net product revenue from initial inventory shipments and bolstered its liquidity position with $413.6 million in cash and marketable securities, significantly aided by a $205 million priority review voucher monetization. The company recorded a net loss of $107.2 million ($0.81 per share) due to heavy investments in commercial infrastructure and R&D for its subcutaneous formulation. Despite the loss, management reported strong early commercial traction, having engaged 95% of top SMA treatment centers and secured payer coverage reach for approximately 47 million lives through Anthem and Centene.
Tickers: $SRRK
Topics: earnings report FDA approval net loss R&D expenses revenue
Read the full article at Motley Fool
Part of the story Scholar Rock Reports Q3 2026 Results Following ISEMBYLD FDA Approval (5 articles)